Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longeveron Inc
(NQ:
LGVN
)
2.280
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Longeveron Inc
< Previous
1
2
3
4
Next >
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
August 15, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call
August 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference
July 29, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on $9M Registered Direct Offering
July 22, 2024
Via
Investor Brand Network
Exposures
Product Safety
5 Stocks in the News to Watch Now: LGVN, PRSO, SIRI, INBS, VTAK
July 19, 2024
Via
AB Newswire
Exposures
Product Safety
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Expands Growing Telecommunications Sector Through New Subsidiary
July 18, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Enters into $9M Registered Direct Offering
July 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted Fast Track Designation for Treatment of Mild Alzheimer’s Disease
July 17, 2024
Via
Investor Brand Network
Exposures
Product Safety
TechMediaBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Lomecel-B(TM) Granted RMAT Designation for the Treatment of Mild Alzheimer’s Disease
July 10, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Elected New Board Member at Annual Stockholder Meeting
July 10, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Strategic Board Appointment of Gene Therapy Pioneer Roger Hajjar, MD
July 08, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) Presentation at Virtual Life Sciences Investor Forum Made Available for Online Viewing
June 21, 2024
Via
Investor Brand Network
Exposures
Product Safety
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
June 21, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
June 18, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for $4.4M, Present at Virtual Life Sciences Investor Forum
June 17, 2024
Via
Investor Brand Network
Exposures
Product Safety
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces CEO Participation in Emerging Growth Conference, Completion of Investigator Meeting for Phase 2b Clinical Trial
June 11, 2024
Via
Investor Brand Network
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Emerging Growth Virtual Conference
June 10, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Launches New Business, Eyes Opportunity in Contract Manufacturing
June 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Set to Participate in Upcoming BIO International Convention 2024
May 28, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Financial Report, Business Update for Q1 2024
May 15, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Planned Transitions for Board of Directors
May 13, 2024
Via
Investor Brand Network
Researchers Link Dietary Fats to Alzheimer’s Disease
May 06, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call/Webcast
May 02, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Presenting at This Week’s Planet MicroCap Showcase
April 29, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase
April 26, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Multimillion-Dollar Warrant Exercise Offering, Public Offering
April 19, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M
April 17, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.